Beam Therapeutics Inc. has announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101, an investigational base-editing therapy for sickle cell disease $(SCD)$ with severe vaso-occlusive crises (VOCs). The updated data, which will be presented in a poster session at the European Hematology Association 2025 Congress in Milan, involves 17 patients. All patients treated with BEAM-101 demonstrated induction of fetal hemoglobin (HbF) levels above 60%, a reduction in sickle hemoglobin (HbS) to below 40%, and resolution of anemia. The company reports that patients experienced rapid neutrophil and platelet engraftment and no VOCs post-engraftment. Enrollment is now complete in both adult and adolescent cohorts, with 30 patients expected to be dosed by mid-2025. Beam will host an investor webcast on June 13, 2025, to discuss these findings.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9468155-en) on June 13, 2025, and is solely responsible for the information contained therein.
精彩评论